DEF 14A: Trevi Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Trevi Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Trevi Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 13, 2024, at 12:30 p.m. Eastern Time, conducted exclusively online.
• Stockholders of record as of April 15, 2024, are eligible to vote on the election of three Class II directors, each to serve until the 2027 Annual Meeting.
• The stockholders will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting in favor of the director nominees and the ratification of Ernst & Young LLP's appointment.
• Stockholders must register online by June 12, 2024, at 5:00 p.m. Eastern Time to attend, vote, and submit questions during the virtual meeting.
• The company plans to mail a Notice of Internet Availability of Proxy Materials on or about May 3, 2024.
• As of April 15, 2024, there were 70,435,093 shares of common stock issued and outstanding, each entitled to one vote.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the virtual meeting format for accessibility and the board's active risk oversight. The sentiment is slightly positive due to these factors.

Positives

• The company is providing access to proxy materials online, reducing paper and mailing costs.
• The virtual meeting format is expected to facilitate stockholder attendance and participation from various locations.
• The Board of Directors is actively involved in risk oversight, both directly and through its committees.
• The company has adopted a code of business conduct and ethics applicable to directors, officers, and employees.

Risks

• The document references 'Risk Factors' in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, indicating inherent business risks.
• Failure to register by the deadline of June 12, 2024 at 5:00 p.m. Eastern Time will prevent stockholders from voting online during the Annual Meeting.

Future Outlook

The document outlines the matters to be voted on at the Annual Meeting and the Board's recommendations, but does not provide specific forward-looking statements about the company's financial performance or business prospects.

Management Comments

• The Board of Directors unanimously recommends that you vote FOR the election of the three nominees to serve as Class II directors.
• The Board of Directors unanimously recommends that you vote FOR the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

Industry Context

This announcement is a standard corporate governance procedure for publicly traded companies, ensuring stockholders have the opportunity to vote on key decisions such as director elections and auditor ratification. The virtual meeting format reflects a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and stock options, is typical for publicly traded biopharmaceutical companies.
• The use of a virtual annual meeting aligns with practices adopted by many companies to increase shareholder participation and reduce costs, similar to companies like Pfizer and Johnson & Johnson.
• The company's audit committee pre-approval policy for audit and non-audit services is consistent with SEC regulations and industry best practices, mirroring policies at companies like Amgen and Gilead Sciences.
• The related person transaction policy, requiring audit committee review and approval for transactions exceeding $120,000, is a standard corporate governance practice, comparable to policies at Biogen and Vertex Pharmaceuticals.

Related Party Transactions

• Since January 1, 2022, the company has engaged in transactions with directors, executive officers, and holders of 5% or more of its voting securities, including private placements and public offerings.
• On April 11, 2022, the company issued shares and pre-funded warrants to 5% stockholders and their affiliates in a private placement for gross proceeds of approximately $55 million.
• On September 27, 2022, the company issued shares and pre-funded warrants in a public offering, with certain 5% stockholders and their affiliates participating.
• Jordyn Saradhi, the daughter of the Chief Executive Officer, has been employed by the company as Director, FP&A and Accounting Operations since May 30, 2023.

Stakeholder Impact

• Shareholders have the opportunity to vote on key corporate governance matters.
• Employees are subject to the company's code of business conduct and ethics.
• Directors and executive officers are subject to limitations on liability and indemnification provisions.

Next Steps

• Stockholders need to review the proxy materials and vote on the proposals.
• Stockholders who wish to attend the virtual Annual Meeting must register by June 12, 2024.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Ernst & Young, Accounting Firm, Corporate Governance, Trevi Therapeutics